Medicines Manufacturing Industry Debate

Full Debate: Read Full Debate
Monday 27th February 2023

(1 year, 9 months ago)

Lords Chamber
Read Full debate Read Hansard Text Watch Debate
Lord Parkinson of Whitley Bay Portrait Lord Parkinson of Whitley Bay (Con)
- View Speech - Hansard - - - Excerpts

I echo the tributes that have been paid in this place today and elsewhere to Kate Bingham for the work she did during the pandemic. The Government have invested more than £405 million to date to secure and scale up the UK’s vaccine manufacturing capabilities to ensure a robust response to Covid and potential future health emergencies. We recently announced a 10-year partnership with Moderna, which will invest in mRNA research and development in the UK, and other examples include Fujifilm, which announced in 2021 a £400 million investment in its site in Billingham, on Teesside, which will more than double the site’s existing development and manufacturing, anticipating the creation of up to 350 skilled jobs.

Lord Kamall Portrait Lord Kamall (Con)
- View Speech - Hansard - -

My Lords, one of my frustrations when I was briefly one of the Ministers for life science was that we would have meetings on life sciences between two or three departments, when in fact many parts of government were working on life sciences. I and other Ministers asked for anyone working on life sciences, whether that be in No. 10, the Treasury, DIT, DHSC, et cetera, to all get together in one room, whether virtual or real, to fully co-ordinate across government. I have recently been told that we are no longer co-ordinating across departments. I ask my noble friend to go back to his department to make sure that we continue to co-ordinate with everyone who is working on life sciences in government, so that we do not have one discussion and then have to talk to people outside the room.

Lord Parkinson of Whitley Bay Portrait Lord Parkinson of Whitley Bay (Con)
- View Speech - Hansard - - - Excerpts

I certainly shall, and through the creation of the Department for Science, Innovation and Technology, the point my noble friend makes is highlighted. This is an area where the UK has a globally unique offer, because we have already established a network of medicines manufacturing innovation centres which the industry can use to develop its own technologies, giving it a competitive edge, so the point he raises is important.